Our pan-cancer analysis reveals GDF6’s unique capacity to stratify these opposing responses; high GDF6 expression associates with anti-PD1 refractoriness but potentiates anti-PD-L1 efficacy, likely through differential modulation of myeloid suppressive cells and antigen presentation machinery. Here, GDF6 is linked to cancer.